Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Protagonist Therapeutics stock

Learn how to easily invest in Protagonist Therapeutics stock.

Protagonist Therapeutics is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 122 staff and has a trailing 12-month revenue of around $35.2 million.

How to buy Protagonist Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – PTGX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Protagonist Therapeutics stock price (NASDAQ: PTGX)

Use our graph to track the performance of PTGX stocks over time.

Protagonist Therapeutics shares at a glance

Information last updated 2023-02-02.
Latest market close$14.33
52-week range$6.91 - $29.25
50-day moving average $10.17
200-day moving average $9.51
Wall St. target price$33.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.58

Buy Protagonist Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Protagonist Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protagonist Therapeutics price performance over time

Historical closes compared with the close of $14.33 from 2023-02-03

1 week (2023-01-31) 7.83%
1 month (2023-01-06) 22.79%
3 months (2022-11-07) 84.90%
6 months (2022-08-05) 25.04%
1 year (2022-02-07) -48.82%
2 years (2021-02-05) -35.97%
3 years (2020-02-07) 74.33%
5 years (2018-02-07) 17.88

Protagonist Therapeutics financials

Revenue TTM $35.2 million
Gross profit TTM $27.4 million
Return on assets TTM -25.15%
Return on equity TTM -45.39%
Profit margin 0%
Book value $4.95
Market capitalisation $703 million

TTM: trailing 12 months

Protagonist Therapeutics share dividends

We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.

Protagonist Therapeutics share price volatility

Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $6.91 up to $29.245. A popular way to gauge a stock's volatility is its "beta".

PTGX.US volatility(beta: 2.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 2.0806. This would suggest that Protagonist Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Protagonist Therapeutics overview

Protagonist Therapeutics, Inc. , a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. .

Frequently asked questions

What percentage of Protagonist Therapeutics is owned by insiders or institutions?
Currently 1.455% of Protagonist Therapeutics shares are held by insiders and 100.147% by institutions.
How many people work for Protagonist Therapeutics?
Latest data suggests 122 work at Protagonist Therapeutics.
When does the fiscal year end for Protagonist Therapeutics?
Protagonist Therapeutics's fiscal year ends in December.
Where is Protagonist Therapeutics based?
Protagonist Therapeutics's address is: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
What is Protagonist Therapeutics's ISIN number?
Protagonist Therapeutics's international securities identification number is: US74366E1029
What is Protagonist Therapeutics's CUSIP number?
Protagonist Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74366E102

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site